aTYR PHARMA INC
No enriched coverage for $ATYR in the last 7 days.
No SEC Form 4 filings for $ATYR in the last 30 days.
See all $ATYR insider activity →aTyr Pharma (NASDAQ:ATYR) reached an agreement with the FDA on the Phase 3 study protocol for efzofitimod, a treatment for pulmonary sarcoidosis. The trial will enroll 372 patients and evaluate lung function and patient-reported outcomes. The company needs additional funding and has $58.9M in cash as of June 30. Shares were down 6.08% to $0.35 at the time of publication.
aTyr Pharma (ATYR) stock rose 9.1% in pre-market trading after aligning with the FDA on a Phase 3 study protocol for efzofitimod, its lead therapeutic candidate. The study, expected to start in Q4 2026, will evaluate efzofitimod in patients with pulmonary sarcoidosis. The company's stock has faced uncertainty but maintains a Buy rating from analysts.
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, sy
Recent ATYR coverage spans corporate actions, regulation and financial news.
Regulatory alignment clears a key hurdle, likely supporting near‑term share price stability and potential upside if trial progresses.
Positive regulatory milestone likely to lift the stock further as the trial timeline becomes clearer.
The FDA alignment clears a key regulatory hurdle, potentially de‑risking the Phase 3 trial and supporting future financing opportunities.
Regulatory timeline update provides clarity for upcoming trial.
New CFO appointment may affect financial strategy and investor perception.
AlphAI scores every news story that mentions ATYR with an AI model for sentiment and relevance, and aggregates insider trades from aTYR PHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
aTyr Pharma (NASDAQ:ATYR) reached an agreement with the FDA on the Phase 3 study protocol for efzofitimod, a treatment for pulmonary sarcoidosis. The trial will enroll 372 patients and evaluate lung function and patient-reported outcomes. The company needs additional funding and has $58.9M in cash as of June 30. Shares were down 6.08% to $0.35 at the time of publication.
2 min readaTyr Pharma (ATYR) stock rose 9.1% in pre-market trading after aligning with the FDA on a Phase 3 study protocol for efzofitimod, its lead therapeutic candidate. The study, expected to start in Q4 2026, will evaluate efzofitimod in patients with pulmonary sarcoidosis. The company's stock has faced uncertainty but maintains a Buy rating from analysts.
2 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, sy
2 min readUniverse Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
2 min readaTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.
3 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD Company awaiting comments f
4 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 30, 2026 (“ Execution Date ”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road, Su
6 min readSCHIMMEL PAUL purchased 100,000 indirectly-held shares of aTYR PHARMA INC (ATYR) at $0.50 on 2026-05-27.
2 min readThis article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.
3 min read
